AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
AccuStem Sciences (OTCQB: ACUT), a clinical stage diagnostics company focused on cancer patient outcomes, has announced that Board Chairman Gabriele Cerrone has increased his stake in the company. The Chairman purchased 152,802 additional ACUT shares through open market transactions, bringing his total shareholding to 4,872,759 shares.
AccuStem Sciences (OTCQB: ACUT), una società di diagnostica in fase clinica focalizzata sui risultati per i pazienti affetti da cancro, ha annunciato che il Presidente del Consiglio Gabriele Cerrone ha aumentato la sua partecipazione nella società. Il Presidente ha acquistato 152.802 azioni ACUT aggiuntive tramite transazioni nel mercato aperto, portando il suo totale a 4.872.759 azioni.
AccuStem Sciences (OTCQB: ACUT), una empresa de diagnóstico en etapa clínica centrada en los resultados de los pacientes con cáncer, ha anunciado que el Presidente de la Junta Gabriele Cerrone ha aumentado su participación en la empresa. El Presidente compró 152.802 acciones adicionales de ACUT a través de transacciones en el mercado abierto, elevando su tenencia total a 4.872.759 acciones.
AccuStem Sciences (OTCQB: ACUT)는 암 환자의 결과에 초점을 맞춘 임상 단계 진단 회사로, 이사회 의장 Gabriele Cerrone가 회사의 지분을 늘렸다고 발표했습니다. 의장은 공개 시장 거래를 통해 152,802 주의 추가 ACUT 주식을 구매하여 총 보유 주식을 4,872,759 주로 늘렸습니다.
AccuStem Sciences (OTCQB: ACUT), une entreprise de diagnostics en phase clinique axée sur les résultats des patients atteints de cancer, a annoncé que le Président du Conseil Gabriele Cerrone a augmenté sa participation dans l'entreprise. Le Président a acheté 152.802 actions ACUT supplémentaires par le biais de transactions sur le marché libre, portant son total à 4.872.759 actions.
AccuStem Sciences (OTCQB: ACUT), ein Unternehmen für klinische Diagnostik, das sich auf die Ergebnisse von Krebspatienten konzentriert, hat bekannt gegeben, dass der Vorsitzende des Vorstands Gabriele Cerrone seinen Anteil am Unternehmen erhöht hat. Der Vorsitzende kaufte 152.802 zusätzliche ACUT-Aktien über Transaktionen am offenen Markt, wodurch sein Gesamtanteil auf 4.872.759 Aktien anstieg.
- Chairman's increased stake demonstrates insider confidence in company
- Significant share purchase of 152,802 shares by company insider
- Chairman now holds substantial position of 4.87M shares
- Company still trades on OTCQB market rather than major exchange
LONDON and PHOENIX, April 08, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board, Mr. Gabriele Cerrone, has notified the Company that he has recently purchased an additional 152,802 ACUT shares in the open market. This brings his total holding to 4,872,759 shares.
About AccuStem
AccuStem is a clinical stage diagnostics company dedicated to optimizing outcomes and quality of life for all patients with cancer. We plan to drive innovation in healthcare by offering proprietary molecular testing that addresses unmet clinical needs from cancer screening through treatment and monitoring. By interrogating novel disease pathways, such as tumor “stemness”, we believe our tools will help care teams better understand the biology of each patient’s cancer, leading to more informed decision making. For more information, please visit www.accustem.com.
Investor and Media Contact:
Wendy Blosser
Email: investors@accustem.com
FAQ
How many shares did AccuStem Sciences Chairman purchase in April 2025?
What is the total shareholding of ACUT's Chairman after the recent purchase?
When did the Chairman of AccuStem Sciences (ACUT) increase his stake?
What type of company is AccuStem Sciences (ACUT)?
